HIGHLIGHTS
- who: Nagisa Godefroy and collaborators from the Centre d'immunologie et des Maladies Infectieuses CIMI-Paris, INSERM, , Paris, France have published the research: Clostridioides difficile Infection Rates after Ceftolozane-Tazobactam and Ceftazidime-Avibactam Treatment Compared to Carbapenem Treatment: A Retrospective Single-Center Study, in the Journal: Hygiene 2021, 1, 99-105. of 27/06/2021
- what: The aim of the study was, therefore, to determine and compare the number of CDI occurring after treatment with CT or CZA and carbapenem (CBP). This study provides reassuring data on CDI risk following CZA or CT use in . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.